(Q34372111)

1 August 2017

title

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function (English)

1 reference

1 August 2017

1 reference

hepatocellular carcinoma

1 reference

Eduardo Díaz-Rubio

6

0 references

Aranzazu Manzano

1 reference

ORCID Public Data File 2021

author name string

Jon Zugazagoitia

1

1 reference

1 August 2017

Aránzazu Manzano

2

1 reference

1 August 2017

Javier Sastre

3

1 reference

1 August 2017

Jose María Ladero

4

1 reference

1 August 2017

Javier Puente

5

1 reference

1 August 2017

publication date

9 August 2012

1 reference

Clinical and Translational Oncology

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

146-153

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Relationships among tests for censored data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0902-3

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22875650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22875650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22875650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12094-012-0902-3

1 reference

1 August 2017

1 reference